Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

Momenta Pharmaceuticals (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“In 2017 we made important progress, despite facing delays and challenges, and we are beginning to see the fruits of our diligent work pay off. With the recent approval and launch of Glatopa 40 mg,  the significant advancements we’ve made across our novel drug portfolio, and the furthering of both M923, our biosimilar HUMIRA^® candidate, and M710, our biosimilar EYLEA^® candidate in collaboration with Mylan, we are well-positioned for a positive year ahead,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals.

Click here to read the full press release.